AR107983A1 - METHODS TO TREAT GASTROINTESTINAL ADVERSE EVENTS RELATED TO THE IMMUNE SYSTEM IN COMBINATION TREATMENTS ANTI-CTLA4 ANTI-PD-1 - Google Patents
METHODS TO TREAT GASTROINTESTINAL ADVERSE EVENTS RELATED TO THE IMMUNE SYSTEM IN COMBINATION TREATMENTS ANTI-CTLA4 ANTI-PD-1Info
- Publication number
- AR107983A1 AR107983A1 ARP170100748A ARP170100748A AR107983A1 AR 107983 A1 AR107983 A1 AR 107983A1 AR P170100748 A ARP170100748 A AR P170100748A AR P170100748 A ARP170100748 A AR P170100748A AR 107983 A1 AR107983 A1 AR 107983A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- integrin
- vedolizumab
- ctla4
- immune system
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Métodos para reducir eventos adversos gastrointestinales relacionados con el sistema inmunitario, tales como colitis y diarrea, en sujetos que se someten a un tratamiento inmunológico, tal como un tratamiento de; oncología inmunológica, tal como un tratamiento de combinación de anticuerpo anti-CTLA4 y un anticuerpo anti-PD-1 para melanomas. En determinados aspectos, los métodos comprenden administrar una cantidad terapéuticamente eficaz de un polipéptido que inhibe la unión de MAdCAM-integrina, tal como un anticuerpo anti-a4b7 integrina, tal como vedolizumab o un anticuerpo relacionado. | Reivindicación 1: Un método para tratar un evento adverso gastrointestinal relacionado con el sistema inmunitario (gi-irAE) en un sujeto mamífero que se somete a un tratamiento con un antagonista de PD-1, un anticuerpo anti-CTLA4, o un antagonista de PD-1 y un anticuerpo anti-CTLA4, que comprende administrar una cantidad terapéuticamente eficaz de un polipéptido que inhibe la unión de MAdCAM-a4b7 integrina al sujeto. Reivindicación 2: El método de la reivindicación 1, en donde el polipéptido que inhibe la unión de MAdCAM-a4b7 integrina es un anticuerpo anti-a4b7 integrina, como un anticuerpo anti-a4b7 integrina que compite con vedolizumab para unir a4b7 integrina, más particularmente, en donde el anticuerpo tiene la especificidad epitópica de vedolizumab, más particularmente en donde el anticuerpo comprende las regiones determinantes de complementariedad (CDR) de vedolizumab, y aun más particularmente en donde el anticuerpo es vedolizumab.Methods to reduce gastrointestinal adverse events related to the immune system, such as colitis and diarrhea, in subjects undergoing immunological treatment, such as a treatment of; Immunologic oncology, such as a combination treatment of anti-CTLA4 antibody and an anti-PD-1 antibody for melanomas. In certain aspects, the methods comprise administering a therapeutically effective amount of a polypeptide that inhibits the binding of MAdCAM-integrin, such as an anti-a4-7 integrin antibody, such as vedolizumab or a related antibody. | Claim 1: A method of treating a gastrointestinal adverse event related to the immune system (gi-irAE) in a mammalian subject that is subjected to a treatment with a PD-1 antagonist, an anti-CTLA4 antibody, or a PD antagonist -1 and an anti-CTLA4 antibody, which comprises administering a therapeutically effective amount of a polypeptide that inhibits the binding of MAdCAM-a4b7 integrin to the subject. Claim 2: The method of claim 1, wherein the polypeptide that inhibits the binding of MAdCAM-a4b7 integrin is an anti-a4b7 integrin antibody, such as an anti-a4b7 integrin antibody that competes with vedolizumab to bind a4b7 integrin, more particularly, wherein the antibody has the epitopic specificity of vedolizumab, more particularly where the antibody comprises the complementarity determining regions (CDR) of vedolizumab, and even more particularly where the antibody is vedolizumab.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662312826P | 2016-03-24 | 2016-03-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR107983A1 true AR107983A1 (en) | 2018-07-04 |
Family
ID=58489429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170100748A AR107983A1 (en) | 2016-03-24 | 2017-03-27 | METHODS TO TREAT GASTROINTESTINAL ADVERSE EVENTS RELATED TO THE IMMUNE SYSTEM IN COMBINATION TREATMENTS ANTI-CTLA4 ANTI-PD-1 |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR107983A1 (en) |
| TW (1) | TW201735949A (en) |
| WO (1) | WO2017165742A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109414502A (en) | 2016-06-12 | 2019-03-01 | 千禧制药公司 | The method for treating inflammatory bowel disease |
| CN109793891A (en) * | 2017-11-17 | 2019-05-24 | 韩震 | Application of the polypeptide compound in the adjuvant that preparation improves therapeutic antibodies curative effect and composition and preparation method thereof |
| WO2021213523A1 (en) * | 2020-04-24 | 2021-10-28 | 信达生物制药(苏州)有限公司 | Uses of combination of anti-pd-1 antibody and anti-ctla-4 antibody in preventing or treating cancer |
| CN111944850B (en) * | 2020-08-28 | 2023-03-31 | 澳门大学 | Preparation method of cell for expressing anti-CD22 chimeric antigen receptor and PD-L1 blocking protein, expression vector and application |
| WO2022178557A2 (en) * | 2021-02-22 | 2022-08-25 | Pandion Operations, Inc. | Pancreas targeted therapeutics and uses thereof |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US748802A (en) | 1904-01-05 | Territory | ||
| JP3101690B2 (en) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | Modifications of or for denatured antibodies |
| WO1989007142A1 (en) | 1988-02-05 | 1989-08-10 | Morrison Sherie L | Domain-modified constant region antibodies |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| DE69330523T4 (en) | 1992-08-21 | 2012-08-23 | Vrije Universiteit Brussel | IMMUNOGLOBULINE WITHOUT LIGHT CHAINS |
| US6838254B1 (en) | 1993-04-29 | 2005-01-04 | Conopco, Inc. | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| EP0808367B1 (en) | 1995-02-10 | 2007-07-11 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressins and uses thereof |
| US7803904B2 (en) | 1995-09-01 | 2010-09-28 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressing and uses thereof |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| US6261804B1 (en) | 1997-01-21 | 2001-07-17 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
| DK1712623T3 (en) | 1997-01-21 | 2012-02-06 | Gen Hospital Corp | Selection of proteins using RNA-protein fusions |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| EP1792991A1 (en) | 1999-08-24 | 2007-06-06 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| AU2001233027A1 (en) | 2000-01-27 | 2001-08-07 | Genetics Institute, Llc | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
| US20010046496A1 (en) | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
| IL149701A0 (en) | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
| CA2464690A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of apolipoprotein d |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| EP1576014B1 (en) | 2002-12-23 | 2011-06-29 | Wyeth LLC | Antibodies against pd-1 and uses thereof |
| US7322582B2 (en) | 2003-07-17 | 2008-01-29 | Mind Wurx, Llc | Enhanced shopping cart with lowered center of gravity and frame therefor |
| GB0400440D0 (en) | 2004-01-09 | 2004-02-11 | Isis Innovation | Receptor modulators |
| CA2552523C (en) | 2004-01-09 | 2019-11-26 | Pfizer Inc. | Monoclonal antibodies to mucosal addressin cell adhesion molecule(madcam) |
| RU2007108538A (en) | 2004-08-11 | 2008-09-20 | Трабьон Фармасьютикалз, Инк. (Us) | LINKED PROTEIN DOMAIN |
| HUE039591T2 (en) | 2004-09-03 | 2019-01-28 | Genentech Inc | Humanized anti-beta7 antagonists and uses therefor |
| US20090252741A1 (en) | 2004-09-08 | 2009-10-08 | Ohio State University Research Foundation | Human monoclonal anti-ctla4 antibodies in cancer treatment |
| KR101339628B1 (en) | 2005-05-09 | 2013-12-09 | 메다렉스, 인코포레이티드 | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101888321B1 (en) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | Human monoclonal antibodies to programmed death ligand 1(pd-l1) |
| WO2007061679A1 (en) | 2005-11-17 | 2007-05-31 | Millennium Pharmaceuticals, Inc. | HUMANIZED IMMUNOGLOBULIN REACTIVE WITH α4β7 INTEGRIN |
| WO2007067959A2 (en) | 2005-12-07 | 2007-06-14 | Medarex, Inc. | Ctla-4 antibody dosage escalation regimens |
| EP2007808A4 (en) | 2006-04-14 | 2010-07-21 | Trubion Pharmaceuticals Inc | Binding proteins comprising immunoglobulin hinge and fc regions having altered fc effector functions |
| PL2170959T3 (en) | 2007-06-18 | 2014-03-31 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| CL2008001933A1 (en) | 2007-06-29 | 2009-09-25 | Millennium Pharm Inc | Pyrimidine derived compounds, raph kinase inhibitors; intermediate compounds; preparation procedure; pharmaceutical composition; and its use to treat proliferative, cardiac, neurodegenerative, inflammatory, bone, immunological, viral disease, among others. |
| EP2240195A4 (en) | 2007-12-12 | 2011-12-21 | Sciclone Pharmaceuticals Inc | Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4) |
| WO2009100140A1 (en) | 2008-02-04 | 2009-08-13 | Medarex, Inc. | Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof |
| US8119129B2 (en) | 2008-08-01 | 2012-02-21 | Bristol-Myers Squibb Company | Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases |
| US7993640B2 (en) | 2008-08-06 | 2011-08-09 | Light Sciences Oncology, Inc. | Enhancement of light activated therapy by immune augmentation using anti-CTLA-4 antibody |
| CA2735006A1 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Pd-1 antagonists and methods of use thereof |
| AU2009290543B2 (en) | 2008-09-12 | 2015-09-03 | Oxford University Innovation Limited | PD-1 specific antibodies and uses thereof |
| CA2736829C (en) | 2008-09-12 | 2018-02-27 | Isis Innovation Limited | Pd-1 specific antibodies and uses thereof |
| WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| WO2010042433A1 (en) | 2008-10-06 | 2010-04-15 | Bristol-Myers Squibb Company | Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases |
| JO3101B1 (en) | 2008-12-02 | 2017-09-20 | Takeda Pharmaceuticals Co | Benzothiazole derivatives as anticancer agents |
| KR20210060670A (en) | 2008-12-09 | 2021-05-26 | 제넨테크, 인크. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| GB0903325D0 (en) | 2009-02-26 | 2009-04-08 | Univ Aberdeen | Antibody molecules |
| WO2010107752A2 (en) | 2009-03-20 | 2010-09-23 | Amgen Inc. | Alpha-4-beta-7 heterodimer specific antagonist antibody |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| US8993731B2 (en) | 2010-03-11 | 2015-03-31 | Ucb Biopharma Sprl | PD-1 antibody |
| US20130156768A1 (en) | 2010-08-26 | 2013-06-20 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with braf inhibitors for the synergistic treatment of proliferative diseases |
| GB201103955D0 (en) | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| WO2012145493A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| CN107998388B (en) | 2011-05-02 | 2023-07-14 | 千禧制药公司 | Preparation of anti-alpha 4 beta 7 antibodies |
| UA116189C2 (en) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | FORMULATION FOR ANTI-α4β7 ANTIBODY |
| WO2013019620A2 (en) | 2011-07-29 | 2013-02-07 | Glaxosmithkline Llc | Method of treating cancer using combination of braf inhibitor, mek inhibitor, and anti-ctla-4 antibody |
| PE20141693A1 (en) | 2011-08-01 | 2014-11-24 | Genentech Inc | METHODS TO TREAT CANCER BY THE USE OF AXIS BINDING ANTAGONISTS PD-1 AND MEK INHIBITORS |
| US20150079100A1 (en) | 2012-03-23 | 2015-03-19 | Bristol-Myers Squibb Company | Methods of treatments using ctla-4 antibodies |
| EP2912063A1 (en) | 2012-10-23 | 2015-09-02 | Bristol-Myers Squibb Company | Combination of anti-kir and anti-ctla-4 antibodies to treat cancer |
| US20140323533A1 (en) | 2013-04-29 | 2014-10-30 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases |
| PT3702373T (en) | 2013-09-13 | 2022-09-27 | Beigene Switzerland Gmbh | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
| IL247320B (en) | 2014-02-21 | 2022-09-01 | Nektar Therapeutics | Use of il -2r beta – selective agonists in combination with anti ctla – 4 or pd - 1 antibodies for treating cancer |
| UY36046A (en) | 2014-03-26 | 2015-10-30 | Millennium Pharm Inc | PHARMACEUTICAL FORMULATIONS, PREPARATION PROCESSES AND METHODS OF USE |
| MX2016014189A (en) | 2014-05-13 | 2017-05-04 | Medimmune Ltd | Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer. |
| CN105296433B (en) | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | A kind of CTLA4 antibody, its medical composition and its use |
| EP3012270A1 (en) * | 2014-10-23 | 2016-04-27 | Institut Gustave Roussy | Products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker |
-
2017
- 2017-03-24 WO PCT/US2017/023981 patent/WO2017165742A1/en active Application Filing
- 2017-03-24 TW TW106110028A patent/TW201735949A/en unknown
- 2017-03-27 AR ARP170100748A patent/AR107983A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017165742A1 (en) | 2017-09-28 |
| TW201735949A (en) | 2017-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR107983A1 (en) | METHODS TO TREAT GASTROINTESTINAL ADVERSE EVENTS RELATED TO THE IMMUNE SYSTEM IN COMBINATION TREATMENTS ANTI-CTLA4 ANTI-PD-1 | |
| PH12018502046A1 (en) | Methods for inhibiting angiogenesis in a subject in need thereof | |
| NI201700015A (en) | JOINT TREATMENTS WITH ANTI CD40 ANTIBODIES | |
| PH12021550023A1 (en) | Humanized anti-tau antibodies | |
| BR112019005823A2 (en) | treatment for refractory migraine | |
| CL2019001411A1 (en) | Methods for inhibition of fibrosis in a subject in need of them. (divisional application 201801817) | |
| EA201891983A1 (en) | COMBINED THERAPY WITH ANTIBODIES TO CD73 | |
| BR112018012929A2 (en) | bispecific anti-cd20 / anti-cd3 antibodies to treat acute lymphoblastic leukemia | |
| EA201691683A1 (en) | ANTIBODIES AGAINST DLL3 AND CONJUGATES ANTIBODY AND MEDICINE FOR USE FOR MELANOMA | |
| EA201990374A1 (en) | COMBINATION OF ANTI-BODY AGAINST CD20, PI3-KINASE-DELTA INHIBITOR AND ANTIBODY AGAINST PD-1 OR AGAINST PD-L1 FOR TREATMENT OF HEMATOLOGICAL CANCER | |
| BR112018072723A2 (en) | composition, and methods for treating a disease in a subject and for enhancing an immune response in a subject | |
| BR112020015915A8 (en) | USES OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-CTLA4 ANTIBODY OR ANTIGEN-BINDING FRAGMENTS THEREOF, AS WELL AS A KIT FOR TREATMENT OF A PATIENT WITH CANCER | |
| MX2018003713A (en) | Preventing, treating, and reducing (persistent) post-traumatic headache. | |
| CO2018007151A2 (en) | Plasma kallikrein inhibitors and their uses to treat hereditary angioedema attack | |
| BR112017020002A2 (en) | COMBINATION OF HDAC INHIBITOR AND ANTI-PD-1 ANTIBODY FOR CANCER TREATMENT | |
| MX2020010269A (en) | Methods of treating ulcerative colitis. | |
| BR112017002433A2 (en) | anti-amide antibodies | |
| CO2021011034A2 (en) | Methods to treat multiple myeloma | |
| EA202191666A1 (en) | ANTIBODIES TO IL-27 AND THEIR USE | |
| MX2019001958A (en) | Methods of treating crohn's disease with an anti-nkg2d antibody. | |
| NZ729878A (en) | Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alpha4beta7 integrin blocking antibodies | |
| EA201891528A1 (en) | COMPOSITIONS AND METHODS OF DETECTION AND TREATMENT OF GASTRIC CANCER | |
| CL2019003485A1 (en) | Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy. (divisional request 201900909) | |
| EA201891529A1 (en) | COMPOSITIONS AND METHODS OF DETECTION AND TREATMENT OF OVARIAN CANCER | |
| MX2022006728A (en) | Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |